Vaxcyte, Inc. (PCVX) vs TG Therapeutics, Inc. (TGTX)
Vaxcyte, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Vaxcyte, Inc. and TG Therapeutics, Inc. are of similar size ($8.8B and $8.5B). Vaxcyte, Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 18.9×. TG Therapeutics, Inc. has the higher net margin (55.2% vs 0.00%) and the higher return on invested capital (10.7% vs −57.3%). Across the 14 metrics below, TG Therapeutics, Inc. leads on 11 and Vaxcyte, Inc. on 3.
Valuation
Profitability
| Metric | PCVX | TGTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 82.37% | 65.16% |
| Operating margin | 0.00% | 17.05% | 0.00% |
| Net margin | 0.00% | 55.22% | 0.00% |
| Free cash flow margin | 0.00% | 2.17% | 0.00% |
| Return on equity | (36.51%) | 100.28% | (57.72%) |
| Return on assets | (33.03%) | 37.70% | (49.22%) |
| Return on invested capital | (57.30%) | 10.69% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack